Compounds > 5-methylangelicin
Page last updated: 2024-12-06

5-methylangelicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID62267
CHEMBL ID352646
CHEBI ID82483
SCHEMBL ID1115503
MeSH IDM0079778

Synonyms (21)

Synonym
5-methyl-2h-furo(2,3-h)-1-benzopyran-2-one
4-hydroxy-6-methyl-5-benzofuranacrylic acid gamma-lactone
2h-furo(2,3-h)(1)benzopyran-2-one, 5-methyl-
brn 4428822
5-methylangelicin
CHEMBL352646
chebi:82483 ,
73459-03-7
C19444
5-methyl-2h-furo(2,3-h)(1)benzopyran-2-one plus ultraviolet a radiation
niosh/lv1453000
2h-furo(2,3-h)(1)benzopyran-2-one, 5-methyl-, plus ultraviolet a radiation
5-methylangelicin plus ultraviolet a radiation
LV14530000
2h-furo(2,3-h)-1-benzopyran-2-one, 5-methyl-
5-methylisopsoralen
SCHEMBL1115503
4-hydroxy-6-methyl-5-benzofuranacrylic acid .gamma.-lactone
5-methyl-2h-furo[2,3-h]chromen-2-one #
DTXSID5036894
Q27155979

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" These studies show that the psoralens with two potential DNA-binding sites (8-MOP and 5-MOP) were more toxic than psoralens with only one photoreactive site (5-MIP and 3-CEP)."( Toxicity of 8-methoxypsoralen, 5-methoxypsoralen, 3-carbethoxypsoralen, or 5-methylisopsoralen with ultraviolet radiation in the hairless (HRA/Skh) mouse.
Davies, RE; Dunnick, JK; Forbes, PD; Iverson, WO, 1987)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
furanocoumarinAny furochromene that consists of a furan ring fused with a coumarin. The fusion may occur in different ways in give several isomers.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID21992Water solubility (solubility in mol/L)1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Methylangelicins: new potential agents for the photochemotherapy of psoriasis. Structure-activity study on the dark and photochemical interactions with DNA.
AID220348Compound was evaluated for association constant in the calf thymus DNA1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Methylangelicins: new potential agents for the photochemotherapy of psoriasis. Structure-activity study on the dark and photochemical interactions with DNA.
AID20131Rate constant of the photoreaction between compound and DNA.1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
4'-Methylangelicins: new potential agents for the photochemotherapy of psoriasis.
AID220351Compound was evaluated for rate constant in the calf thymus DNA1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Methylangelicins: new potential agents for the photochemotherapy of psoriasis. Structure-activity study on the dark and photochemical interactions with DNA.
AID68590Compound was evaluated for the inhibition of DNA synthesis in Ehrlich Ascites tumor cells by irradiation (365 nm) at 1.9 x 10 e-5M1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Methylangelicins: new potential agents for the photochemotherapy of psoriasis. Structure-activity study on the dark and photochemical interactions with DNA.
AID68591Compound was evaluated for the inhibition of RNA synthesis in Ehrlich Ascites tumor cells by irradiation (365 nm) at 1.9 x 10 e-5M1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Methylangelicins: new potential agents for the photochemotherapy of psoriasis. Structure-activity study on the dark and photochemical interactions with DNA.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (75.00)18.7374
1990's4 (25.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.49 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
5-methoxypsoralen
5-Methoxypsoralen: A linear furanocoumarin that has phototoxic and anti-inflammatory properties, with effects similar to METHOXSALEN. It is used in PUVA THERAPY for the treatment of PSORIASIS.. 5-methoxypsoralen : A 5-methoxyfurocoumarin that is psoralen substituted by a methoxy group at position 5.		2.37205-methoxyfurocoumarin;
organic heterotricyclic compound;
psoralens		hepatoprotective agent;
plant metabolite
methoxsalen
Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.. methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis.		3.0650aromatic ether;
psoralens		antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite
trioxsalen
Trioxsalen: Pigmenting photosensitizing agent obtained from several plants, mainly Psoralea corylifolia. It is administered either topically or orally in conjunction with ultraviolet light in the treatment of vitiligo.. lactone : Any cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.. antipsoriatic : A drug used to treat psoriasis.. trioxsalen : 7H-Furo[3,2-g]chromen-7-one in which positions 2, 5, and 9 are substituted by methyl groups. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered orally in conjunction with UV-A for phototherapy treatment of vitiligo. After photoactivation it creates interstrand cross-links in DNA, inhibiting DNA synthesis and cell division, and can lead to cell injury; recovery from the cell injury may be followed by increased melanisation of the epidermis.		2.6630psoralensdermatologic drug;
photosensitizing agent
bromodeoxyuridine
Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.		1.9710pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
ficusin
Ficusin: A naturally occurring furocoumarin, found in PSORALEA. After photoactivation with UV radiation, it binds DNA via single and double-stranded cross-linking.. psoralen : The simplest member of the class of psoralens that is 7H-furo[3,2-g]chromene having a keto group at position 7. It has been found in plants like Psoralea corylifolia and Ficus salicifolia.		1.9610psoralensplant metabolite
imperatorin
imperatorin: tumor necrosis factor antagonist; furanocoumarin from West African medicinal plant Clausena anisata; structure in Negwer, 5th ed, #3005. imperatorin : A member of the class of psoralens that is psoralen substituted by a prenyloxy group at position 8. Isolated from Angelica dahurica and Angelica koreana, it acts as a acetylcholinesterase inhibitor.		1.9610psoralensEC 3.1.1.7 (acetylcholinesterase) inhibitor;
metabolite
angelicin
angelicin: used as tranquillizer; sedative; or anticonvulsant; structure		2.8840furanocoumarin
4,5'-dimethylangelicin
[no description available]		2.3720furanocoumarin
3-carbethoxypsoralen
[no description available]		2.3720ethyl ester;
psoralens
4,4'-dimethylangelicin
4,4'-dimethylangelicin: structure given in first source		2.3720furanocoumarin
4-methylangelicin
[no description available]		2.6630
pyrimidine dimers
Pyrimidine Dimers: Dimers found in DNA chains damaged by ULTRAVIOLET RAYS. They consist of two adjacent PYRIMIDINE NUCLEOTIDES, usually THYMINE nucleotides, in which the pyrimidine residues are covalently joined by a cyclobutane ring. These dimers block DNA REPLICATION.		2.3720
hydroxymethyltrioxsalen
[no description available]		2.3720
4,4',6-trimethylangelicin
4,4',6-trimethylangelicin: new monofunctional furocoumarin; potential agent for photochemotherapy of psoriasis; capable of photoreacting with DNA to a large extent forming only monoadducts; produces singlet oxygen to an insignificant extent; structure given in first source		1.9610furanocoumarin
ConditionIndicatedRelationship StrengthStudiesTrials
Palmoplantaris Pustulosis
[description not available]		02.6530
Psoriasis
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.		02.6530
Anemia, Hypoplastic
[description not available]		01.9610
Anemia, Fanconi
[description not available]		01.9610
Kaposi Disease
[description not available]		02.8840
Anemia, Aplastic
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.		01.9610
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		01.9610
Xeroderma Pigmentosum
A rare, pigmentary, and atrophic autosomal recessive disease. It is manifested as an extreme photosensitivity to ULTRAVIOLET RAYS as the result of a deficiency in the enzyme that permits excisional repair of ultraviolet-damaged DNA.		02.8840
Carcinoma, Ehrlich Tumor
A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.		02.3720
Actinic Reticuloid Syndrome
[description not available]		01.9710
Experimental Neoplasms
[description not available]		01.9710
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9710
Cataract, Membranous
[description not available]		01.9610
Leukoma
[description not available]		01.9610
Cataract
Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)		01.9610
Corneal Opacity
Disorder occurring in the central or peripheral area of the cornea. The usual degree of transparency becomes relatively opaque.		01.9610